StreetAlpha
13F holdings · Q3 2026

Great Point Partners

Greenwich, CT · files as Great Point Partners LLC
Know the moment Great Point Partners filesYou follow Great Point Partners An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1281446

Great Point Partners reported 41 stocks worth $381M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are VERA (6.8%), VOR (5.6%) and AMLX (5.3%). Compared with Q2 2026, the fund opened new positions in IONS, GMAB and BLTE, added to VERA, DFTX and LBRX, trimmed VOR, SGMT and SLGL and sold out of ALMS, IMMX and SLN.

Latest filing: what Great Point Partners did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
9 new4 added11 trimmed5 sold outBought about $95.4M · sold about $101M
New 9
See all 9 →
Added 4
Trimmed 11
  • ORKA−$13.2M−87%
  • VOR−$10.9M−34%
  • CTNM−$9.9M−80%
  • IRD−$5.8M−61%
  • ABVX−$4.9M−24%
See all 11 →
Sold out 5

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$381M−10.2% vs last quarter · $418M including options
Stocks held419 new · 5 sold out
Top 5 weight28.0%spread out
Turnover52%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
VERA
Vera Therapeutics Inc
$26.1M6.8%809K+208K (+35%)3 of 8
2
VOR
Vor Biopharma Inc Com New
$21.5M5.6%1.1M−573K (−34%)4 of 8
3
AMLX
Amylyx Pharmaceuticals Inc
$20.4M5.3%700KNo change7 of 8
4
SGMT
Sagimet Biosciences Inc
$19.4M5.1%2M−68K (−3%)2 of 8
5
DFTX
Definium Therapeutics Inc
$19.4M5.1%509K+84K (+20%)2 of 8
6
IONS
Ionis Pharmaceuticals Inc
$18.8M4.9%420KNew position5 of 8
7
GMAB
Genmab A/s
$18.7M4.9%525KNew position1 of 8
8
SLGL
Sol Gel Technologies
$17.8M4.7%239K−35K (−13%)3 of 8
9
ZURA
Zura Bio Ltd
$17M4.5%4.1M−139K (−3%)8 of 8
10
LBRX
LB Pharmaceuticals Inc
$15.8M4.1%410K+93K (+29%)3 of 8
🔒 31 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
ALMS
Alumis Inc
$24.1M856K
IMMX
Immix Biopharma Inc
$13.2M1.3M
SLN
Silence Therapeutics PLC
$4.9M450K
PALI
Palisade Bio Inc
$4.8M2.3M
PMN
Promis Neurosciences Inc
$1.1M86K

Options

valued at the underlying shares
StockTypeValueSharesChange
IBRX
Immunitybio Inc
Put$28.3M3M0
PHVS
Pharvaris N V
Put$4.8M150K+150,000
CTNM
Contineum Therapeutics Inc
Call$4M300K+300,000
ANNX
Annexon Inc
Call$412K97K+97,300

Reported value

last 8 quarters
$212MQ4 '24
$184MQ1 '25
$154MQ2 '25
$240MQ3 '25
$308MQ4 '25
$408MQ1 '26
$424MQ2 '26
$381MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Great Point Partners 13F FAQ

What does Great Point Partners own?

Great Point Partners reported 41 stocks worth $381M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are VERA (6.8%), VOR (5.6%) and AMLX (5.3%). The table above lists every position in the filing (the top 10 without an account).

What did Great Point Partners buy and sell in Q3 2026?

Compared with Q2 2026: 9 new positions, 4 added to, 11 trimmed and 5 sold out. New positions include IONS, GMAB and BLTE. It sold all of ALMS, IMMX and SLN.

When will Great Point Partners file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Great Point Partners's portfolio worth?

The Q3 2026 filing reports $381M in US stocks ($418M including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.